Study: NCT01250496

Adverse event: Flushing
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Flushing sensation occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 7 affected / 124 at risk

Adverse event: Dyspnoea
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Dyspnea sensation occuring any time after the administration of regadenoson until the patient's dismissal from the nuclear laboratory.
Frequency: 14 affected / 124 at risk

Adverse event: Headache
Serious: no
Organ System: Nervous system disorders
Notes: Headache symptoms occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 9 affected / 124 at risk

Adverse event: Chest discomfort or pain
Serious: no
Organ System: Cardiac disorders
Notes: Chest discomfort occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 13 affected / 124 at risk

Adverse event: Feeling hot
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Hot sensation occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 11 affected / 124 at risk

Adverse event: Nausea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Nausea occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 21 affected / 124 at risk

Adverse event: Abdominal cramp or discomfort
Serious: no
Organ System: Gastrointestinal disorders
Notes: Abdominal cramps or discomfort occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 10 affected / 124 at risk

Adverse event: Dizziness
Serious: no
Organ System: Nervous system disorders
Notes: Dizziness symptoms occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 31 affected / 124 at risk

Adverse event: Diarrhoea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Diarrhea or loose bowel movement occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 4 affected / 124 at risk

Adverse event: Open label aminophylline use
Serious: no
Organ System: Injury, poisoning and procedural complications
Notes: Intravenous aminophylline to treat regadenoson-related side effects, administered after regadenoson injection
Frequency: 1 affected / 124 at risk

Adverse event: Atrial fibrillation
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting atrial fibrillation, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk

Adverse event: Supraventricular tachycardia
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting supraventricular tachycardia, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk

Adverse event: Ventricular tachycardia
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting non-sustained ventricular tachycardia, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk

Adverse event: Flushing
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Flushing sensation occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 6 affected / 124 at risk

Adverse event: Dyspnoea
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Dyspnea sensation occuring any time after the administration of regadenoson until the patient's dismissal from the nuclear laboratory.
Frequency: 23 affected / 124 at risk

Adverse event: Headache
Serious: no
Organ System: Nervous system disorders
Notes: Headache symptoms occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 31 affected / 124 at risk

Adverse event: Chest discomfort or pain
Serious: no
Organ System: Cardiac disorders
Notes: Chest discomfort occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 15 affected / 124 at risk

Adverse event: Feeling hot
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Hot sensation occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 12 affected / 124 at risk

Adverse event: Nausea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Nausea occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 22 affected / 124 at risk

Adverse event: Abdominal cramp or discomfort
Serious: no
Organ System: Gastrointestinal disorders
Notes: Abdominal cramps or discomfort occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 17 affected / 124 at risk

Adverse event: Dizziness
Serious: no
Organ System: Nervous system disorders
Notes: Dizziness symptoms occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 45 affected / 124 at risk

Adverse event: Diarrhoea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Diarrhea or loose bowel movement occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 13 affected / 124 at risk

Adverse event: Open label aminophylline use
Serious: no
Organ System: Injury, poisoning and procedural complications
Notes: Intravenous aminophylline to treat regadenoson-related side effects, administered after regadenoson injection
Frequency: 7 affected / 124 at risk

Adverse event: Atrial fibrillation
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting atrial fibrillation, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk

Adverse event: Supraventricular tachycardia
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting supraventricular tachycardia, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk

Adverse event: Ventricular tachycardia
Serious: no
Organ System: Cardiac disorders
Notes: Self-limiting non-sustained ventricular tachycardia, not requiring treatment, occurring anytime after the administration of regadenoson until the patient's dismissal from the nuclear laboratory
Frequency: 1 affected / 124 at risk